154 related articles for article (PubMed ID: 20375656)
1. Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region.
Ito M; Kimura H; Yoshida K; Kimura Y; Ozaki N; Kurita K
Clin Neuropharmacol; 2010; 33(2):79-83. PubMed ID: 20375656
[TBL] [Abstract][Full Text] [Related]
2. The dubious effect of milnacipran for the treatment of burning mouth syndrome.
Sugimoto K
Clin Neuropharmacol; 2011; 34(4):170-3. PubMed ID: 21738026
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels of milnacipran and its effectiveness for the treatment of chronic pain in the orofacial region.
Kimura H; Yoshida K; Ito M; Tokura T; Nagashima W; Kurita K; Ozaki N
Hum Psychopharmacol; 2012 May; 27(3):322-8. PubMed ID: 22585592
[TBL] [Abstract][Full Text] [Related]
4. Milnacipran for chronic pain in the orofacial region.
Pae CU
Clin Neuropharmacol; 2010; 33(5):270. PubMed ID: 20864840
[No Abstract] [Full Text] [Related]
5. Duloxetine Plasma Concentrations and Its Effectiveness in the Treatment of Nonorganic Chronic Pain in the Orofacial Region.
Kobayashi Y; Nagashima W; Tokura T; Yoshida K; Umemura E; Miyauchi T; Arao M; Ito M; Kimura H; Kurita K; Ozaki N
Clin Neuropharmacol; 2017; 40(4):163-168. PubMed ID: 28622208
[TBL] [Abstract][Full Text] [Related]
6. Milnacipran dose-effect study in patients with burning mouth syndrome.
Kato Y; Sato T; Katagiri A; Umezaki Y; Takenoshita M; Yoshikawa T; Sato Y; Toyofuku A
Clin Neuropharmacol; 2011; 34(4):166-9. PubMed ID: 21738023
[TBL] [Abstract][Full Text] [Related]
7. Milnacipran for the drastic improvement of refractory pain in a patient without depressive symptoms: a case report.
Kito S; Nakajima T; Koga Y
Eur Psychiatry; 2005 Jun; 20(4):355. PubMed ID: 16018932
[No Abstract] [Full Text] [Related]
8. Therapeutic effects of milnacipran (serotonin noradrenalin reuptake inhibitor) on depression following mild and moderate traumatic brain injury.
Kanetani K; Kimura M; Endo S
J Nippon Med Sch; 2003 Aug; 70(4):313-20. PubMed ID: 12928711
[TBL] [Abstract][Full Text] [Related]
9. Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports.
Takahashi H; Kamata M; Yoshida K; Higuchi H; Shimizu T
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):351-3. PubMed ID: 15694247
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effects of the selective serotonin noradrenaline reuptake inhibitor milnacipran on depressive symptoms in patients with Alzheimer's disease.
Mizukami K; Hatanaka K; Tanaka Y; Sato S; Asada T
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):349-52. PubMed ID: 19166899
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of milnacipran for a patient with pain disorder and long QT syndrome.
Ikawa M; Yamada K
Clin Neuropharmacol; 2010 May; 33(3):163-4. PubMed ID: 20173629
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of milnacipran: placebo-controlled trials.
Lecrubier Y; Pletan Y; Solles A; Tournoux A; Magne V
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():29-33. PubMed ID: 8923124
[TBL] [Abstract][Full Text] [Related]
13. Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium.
Bernstein CD; Albrecht KL; Marcus DA
Expert Opin Pharmacother; 2013 May; 14(7):905-16. PubMed ID: 23506481
[TBL] [Abstract][Full Text] [Related]
14. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.
Welsch P; Üçeyler N; Klose P; Walitt B; Häuser W
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD010292. PubMed ID: 29489029
[TBL] [Abstract][Full Text] [Related]
15. Milnacipran plasma levels and antidepressant response in Japanese major depressive patients.
Higuchi H; Yoshida K; Takahashi H; Naito S; Kamata M; Ito K; Sato K; Tsukamoto K; Shimizu T; Nakanishi M; Hishikawa Y
Hum Psychopharmacol; 2003 Jun; 18(4):255-9. PubMed ID: 12766929
[TBL] [Abstract][Full Text] [Related]
16. Milnacipran and selective serotonin reuptake inhibitors in major depression.
Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126
[TBL] [Abstract][Full Text] [Related]
17. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome.
Häuser W; Urrútia G; Tort S; Uçeyler N; Walitt B
Cochrane Database Syst Rev; 2013 Jan; (1):CD010292. PubMed ID: 23440848
[TBL] [Abstract][Full Text] [Related]
18. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results.
Kasper S; Pletan Y; Solles A; Tournoux A
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():35-9. PubMed ID: 8923125
[TBL] [Abstract][Full Text] [Related]
19. The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain.
Obata H; Saito S; Koizuka S; Nishikawa K; Goto F
Anesth Analg; 2005 May; 100(5):1406-1410. PubMed ID: 15845695
[TBL] [Abstract][Full Text] [Related]
20. Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain.
Leo RJ; Brooks VL
Curr Opin Investig Drugs; 2006 Jul; 7(7):637-42. PubMed ID: 16869117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
